So, here's a thing that happens in biotech: a company announces some good data from a clinical trial, and its stock goes up. It's a classic move. On Monday, that company was Vertex Pharmaceuticals (VRTX), and the good news came from a kidney disease drug trial.

Vertex said its Phase 3 RAINIER trial for a drug called povetacicept hit its goals in a 36-week interim look. The trial is for a condition called immunoglobulin A nephropathy, or IgAN, which is a kidney disease. The drug is what's known as a dual inhibitor, meaning it blocks two specific cytokines (BAFF and APRIL, if you're into the science) that are involved in the disease process.

The main goal was to reduce protein in the urine, measured by something called the urine protein to creatinine ratio (UPCR). Patients on the drug saw a 52% reduction from their baseline levels. More importantly, that was a 49.8% greater reduction than what was seen in patients on a placebo, and the difference was both statistically significant and considered clinically meaningful. That's the kind of result that makes regulators and investors pay attention.

The trial also hit its secondary objectives. There was a 77.4% reduction in a specific biomarker called serum galactose deficient IgA1. And for patients who had blood in their urine (hematuria) at the start, a whopping 85.1% saw it resolve.

Vertex's CEO, Reshma Kewalramani, was understandably pleased. "The Phase 3 RAINIER 36-week interim analysis results in IgAN are remarkable," she said. "With its clinical profile, dosing and administration advantage, and breadth of potential indications, povetacicept demonstrates best-in-class potential and establishes renal medicine as Vertex's fourth franchise alongside cystic fibrosis, hematology and acute pain."

The path to market is already moving. The FDA has granted a rolling review for the Biologics License Application (BLA) for povetacicept in IgAN. That means Vertex can submit parts of the application as they're ready, rather than waiting to send one giant package. The company plans to complete the full submission by the end of March, which could set it up for a potential accelerated approval. The final analysis of this trial is still expected after two full years of treatment.

Investors liked what they heard. After the closing bell on Monday, Vertex shares were up more than 6%, trading around $490 in the after-hours session. It's a nice bump for a company looking to build a new pillar of its business beyond its core cystic fibrosis franchise.